Cent Eur J Public Health 2019, 27(3):229-234 | DOI: 10.21101/cejph.a5416

Late presentation among patients with human immunodeficiency virus infection in Turkey

Hayat Kumbasar Karaosmanoğlu1, Bilgül Mete2, Alper Gündüz3, Özlem Altuntaº Aydin1, Fatma Sargin4, Dilek Yildiz Sevgi3, Bülent Durdu5, İlyas Dökmetaº3, Fehmi Tabak2
1 Department of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
2 Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
3 Department of Infectious Diseases and Clinical Microbiology, Sisli Hamidiye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
4 Department of Infectious Diseases and Clinical Microbiology, Göztepe Training and Research Hospital, Medeniyet University, Istanbul, Turkey
5 Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Bezmi Alem University, Istanbul, Turkey

Objective: Late presentation of the patients with human immunodeficiency virus (HIV) infection is associated with less favourable treatment responses, more accelerated clinical progression, and a higher mortality risk. Although HIV prevalence is low in Turkey, it is steadily increasing and the information about late presentation among HIV-positives is limited. We aimed to analyze the status of late presentation among HIV-positive patients in Turkey.

Methods: All newly diagnosed HIV/AIDS patients from 2003 to 2016 were enrolled in this study by five dedicated centres in Istanbul, Turkey. Demographic data, CD4+ counts, and HIV RNA were collected from medical records and were transferred to a HIV database system. Late pre- sentation was defined as presentation for care with a CD4 count < 350 cells/mm3 or presentation with an AIDS-defining event, regardless of the CD4 cell count. A medical literature search was done for the analysis of late presentation in Turkey.

Results: The cohort included 1,673 patients (1,440 males, median age 35 years). Among them, 847 (50.6%) had an early diagnosis, with a CD count of more than 350 cells/mm3. The remaining 826 were late presenters. Among late presenters, 427 (25.5% of all, 51.7% of late presenters) presented with advanced HIV disease. Late presenters were more elderly and less educated. The gender seemed comparable between groups. Late presentation was more likely among married patients. Early presenters were more likely among homosexuals, those diagnosed in screening studies, and in lower HIV-RNA viral load category. There has been a decreasing trend among late presenters in 2011-2016 when compared to 2003-2011 period.

Conclusion: Current data suggest that half of HIV-infected patients present late in Turkey. In our cohort, those presented late were more elderly, less educated, married and had heterosexual intercourse. On admission, late presenters had more HIV-related diseases and were more likely in higher HIV-RNA category. In the cohort, men having sex with men were less likely late presenters. Efforts to reduce the proportion of late presentation are essential for almost every country. The countries should identify the risk factors of late presentation and should improve early diagnosis and presentation for HIV care.

Keywords: late presentation, human immunodeficiency virus infection, acquired immunodeficiency syndrome

Received: June 4, 2018; Revised: June 30, 2019; Accepted: June 30, 2019; Published: September 30, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karaosmanoğlu HK, Mete B, Gündüz A, Aydin ÖA, Sargin F, Sevgi DY, et al.. Late presentation among patients with human immunodeficiency virus infection in Turkey. Cent Eur J Public Health. 2019;27(3):229-234. doi: 10.21101/cejph.a5416. PubMed PMID: 31580559.
Download citation

References

  1. Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, Dickmeiss E, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299(6692):154-7. Go to original source... Go to PubMed...
  2. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS. 2004;18(1):89-97. Go to original source... Go to PubMed...
  3. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007;39(1):51-7. Go to original source... Go to PubMed...
  4. Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir Ther. 2010;15 Suppl 1:31-5. Go to original source... Go to PubMed...
  5. World Health Organization. Guideline on when to start antiretroviraltherapy and on pre-exposure prophylaxis for HIV [Internet]. Geneva: WHO; 2015 [cited 2019 Jun 25]. Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en.
  6. European AIDS Clinical Society (EACS). Guidelines [Internet]. 2015 [cited 2019 Jun 25]. Available from: http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf.
  7. Waters L, Ahmed N, Angus B, Boffito M, Bower M, Churchill D, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 [Internet]. BHIVA; 2016 [cited 2019 June 25]. Available from: http://www.bhiva.org/HIV-1-treatment-guidelines.aspx.
  8. TEMPRANO ANRS 12136 Study Group. A Trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-22. Go to original source... Go to PubMed...
  9. D'Arminio Monforte A, Antinori A, Girardi E, Ceccherini-Silberstein F, Marchetti G, Sabin CA, et al. HIV-infected late presenter patients. AIDS Res Treat. 2012;2012:902679. doi: 10.1155/2012/902679. Go to original source... Go to PubMed...
  10. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al.; European Late Presenter Consensus Working Group. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61-4. Go to original source... Go to PubMed...
  11. Aydin OA, Karaosmanoğlu HK, Korkusuz R, Nazlican O. Toxoplasma gondii IgG seroprevalence in HIV/AIDS patients. Turkiye Parazitol Derg. 2011;35(2):65-7. (In Turkish.) Go to original source... Go to PubMed...
  12. Karaosmanoglu HK, Aydin OA, Nazlican O. Profile of HIV/AIDS patients in a tertiary hospital in Istanbul, Turkey. HIV Clin Trials. 2011;12(2):104-8. Go to original source... Go to PubMed...
  13. Karaosmanoglu HK, Aydin OA, Johansen IS, Korkusuz R, Nazlican O. Late presenters and significance of screening tests in early diagnosis of HIV infection in Istanbul. HealthMED. 2013;7(4):1187-91.
  14. Yemisen M, Aydin OA, Gunduz A, Ozgunes N, Mete B, Ceylan B, et al. Epidemiological profile of naive HIV-1/AIDS patients in Istanbul: the largest case series from Turkey. Curr HIV Res. 2014;12(1):60-4. Go to original source... Go to PubMed...
  15. Aydin ÖA, Karaosmanoğlu HK, Korkusuz R, Özeren M, Özcan N. Mucocutaneous manifestations and the relationship to CD4 lymphocyte counts among Turkish HIV/AIDS patients in Istanbul, Turkey. Turk J Med Sci. 2015;45(1):89-92. Go to original source...
  16. Çerçi P, İnkaya AÇ, Alp ª, Tümer A, Ünal S. Evaluation of 255 HIV/AIDS cases: Hacettepe cohort, Ankara, Turkey. Mikrobiyol Bul. 2016;50(1):94-103. (In Turkish.) Go to original source... Go to PubMed...
  17. HATAM. HIV/AIDS cases according to the year of distribution [Internet]. Ankara: Ministry of Health of Turkey; 2016 [cited 2019 June 25]. Available from: http://www.hatam.hacettepe.edu.tr/AIDS_web-2016.pdf. (In Turkish.)
  18. Sargin F, Yildiz D, Aydin OA, Mete B, Gunduz A, Karaosmanoglu HK, et al. Changes in HIV demographic patterns in a low prevalence population: no evidence of a shift towards men who have sex with men. Int J Infect Dis. 2016;48:52-6. Go to original source... Go to PubMed...
  19. Aydin OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlican O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis. 2013;17(6):707-11. Go to original source... Go to PubMed...
  20. Sayan M, Simºek F, Ceran N, Dokuzoğuz B, Eraksoy H. APOBEC3 hypermutations in HIV-1 infected cases in Turkey. Mikrobiyol Bul. 2013;47(3):482-92. (In Turkish.) Go to original source... Go to PubMed...
  21. Yalçinkaya T, Köse S. Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases. Mikrobiyol Bul. 2014;48(4):585-95. (In Turkish.) Go to original source... Go to PubMed...
  22. Aydin ÖA, Karaosmanoğlu HK, Sayan M, İnce ER, Nazlican Ö. Seroprevalence and risk factors of syphilis among HIV/AIDS patients in Istanbul, Turkey. Cent Eur J Public Health. 2015;23(1):65-8. Go to original source... Go to PubMed...
  23. Sayan M, Sargin F, Inan D, Sevgi DY, Celikbas AK, Yasar K, et al. HIV-1 transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkey. AIDS Res Hum Retroviruses. 2016;32(1):26-31. Go to original source... Go to PubMed...
  24. Sayan M, Gündüz A, Ersöz G, İnan A, Deveci A, Özgür G, et al. Integrase Strand Transfer Inhibitors (INSTIs) resistance mutations in HIV-1 infected Turkish patients. HIV Clin Trials. 2016;17(3):109-13. Go to original source... Go to PubMed...
  25. Kozak M, Zinski A, Leeper C, Willig JH, Mugavero MJ. Late diagnosis, delayed presentation and late presentation in HIV: proposed definitions, methodological considerations and health implications. Antivir Ther. 2013;18(1):17-23. Go to original source...
  26. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18(16):2145-51. Go to original source... Go to PubMed...
  27. Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, et al.; UK CHIC Study. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med. 2007;8(3):135-41. Go to original source... Go to PubMed...
  28. Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, Weber R, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008; 9(6):397-405. Go to original source... Go to PubMed...
  29. Leutscher PD, Laursen T, Andersen B, Ostergaard L, Laursen A, Larsen CS. HIV late presenters in Denmark: need for increased diagnostic awareness among general practitioners. Dan Med Bull. 2011;58(4):A4253.
  30. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007;12(1):89-96. Go to original source...
  31. Borghi V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr. 2008;49(3):282-6. Go to original source... Go to PubMed...
  32. Hachfeld A, Ledergerber B, Darling K, Weber R, Calmy A, Battegay M, et al.; Swiss HIV Cohort Study. Reasons for late presentation to HIV care in Switzerland. J Int AIDS Soc. 2015 Nov 18;18:20317. doi: 10.7448/IAS.18.1.20317. Go to original source... Go to PubMed...
  33. The late presenters working group in COHERE in EuroCoord. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070. Go to original source... Go to PubMed...
  34. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther. 2010;15 Suppl 1:3-8. Go to original source... Go to PubMed...
  35. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, et al.; French Hospital Database ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr. 2013;64(2):197-203. Go to original source...
  36. Helleberg M, Engsig FN, Kronborg G, Laursen AL, Pedersen G, Larsen O, et al. Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort. Scand J Infect Dis. 2012;44(4):282-8. Go to original source... Go to PubMed...
  37. Jeong SJ, Italiano C, Chaiwarith R, Ng OT, Vanar S, Jiamsakul A, et al. Late presentation into care of HIV disease and its associated factors in Asia: results of TAHOD. AIDS Res Hum Retroviruses. 2016;32(3):255-61. Go to original source... Go to PubMed...
  38. Agaba PA, Meloni ST, Sule HM, Agbaji OO, Ekeh PN, Job GC, et al. Patients who present late to HIV care and associated risk factors in Nigeria. HIV Med. 2014;15(7):396-405. Go to original source... Go to PubMed...